Drugs / VH4004280
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06168318 | Dec 2023 → Jun 2024 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT06012136 | Aug 2023 → Jun 2026 overdue | HIV infectious disease | ViiV Healthcare | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05163522 | Dec 2021 → Jun 2023 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06039579 | Oct 2023 → Jun 2024 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VH4004280 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06039579 ↗ |
| Known as | VH-280 | “The pharmacokinetics, drug-drug interaction potential, and safety of a new HIV-1 capsid inhibitor, VH4004280 (VH-280), are described in this first-time-in-human study.” PMID 40287607 ↗ Apr 2025 |
| Action | Inhibit | “HIV-1 capsid inhibitor” NCT05163522 ↗ |
| Route | Oral | “single oral dose of 10 mg VH4004280 PiB” NCT05163522 ↗ |